GW Pharmaceuticals Plc (NASDAQ:GWPH) is expected to report third quarter earnings results, before market open, on Tuesday 3rd November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.83 per share from revenue of $ 127.37 million.
Looking ahead, the full year loss are expected at $ 2.28 per share on the revenues of $ 510.40 million.
Previous Quarter Performance
GW Pharmaceuticals Plc reported loss for the second quarter of $ 0.02 per share, from the revenue of $ 120.63 million. The quarterly revenues raised 207.34 percent compared with the same quarter last year. Street analysts expected GW Pharmaceuticals Plc to report loss of $ 0.85 per share on revenue of $ 108.36 million for the second quarter. The bottom line results beat street analysts by $ 0.83 or 97.65 percent, at the same time, top line results outshined analysts by $ 12.27 million or 11.32 percent.
Stock Performance
Shares of GW Pharmaceuticals Plc traded low $ -0.72 or -0.80 percent on Monday, reaching $ 89.29 with volume of 435.80 thousand shares. GW Pharmaceuticals Plc has traded high as $ 91.02 and has cracked $ 87.51 on the downward trend
The closing price of $ 89.29, representing a 32.41 % increase from the 52 week low of $ 67.98 and a 36.6 % decrease over the 52 week high of $ 141.98.
The company has a market capital of $ 2.47 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Conference Call
GW Pharmaceuticals Plc will be hosting a conference call at 8:30 AM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.gwpharm.com
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis.
